GlassScriptPhysician profile
Nancy Ck Pang
NPI 1538173885
$1,064.97
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $926 · 2020: $119 · 2022: $19.58.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $247.38 | 2019 | |
| Amgen INC. | $150.19 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $98.51 | 2019-2020 | |
| Daiichi Sankyo INC. | $69.12 | 2019-2020 | |
| Glaxosmithkline, LLC. | $63.10 | 2019-2020 | |
| Pfizer INC. | $60.81 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $57.05 | 2019 | |
| Allergan, INC. | $51.92 | 2019 | |
| Astellas Pharma US INC | $37.38 | 2019 | |
| Horizon Therapeutics Plc | $36.47 | 2019 | |
| Novo Nordisk INC | $35.10 | 2019 | |
| Mdd US Operations, LLC | $30.18 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $24.26 | 2019 | |
| Organon LLC | $19.58 | 2022 | |
| Dynavax Technologies Corporation | $18.61 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $17.96 | 2019 | |
| Amarin Pharma, INC. | $16.98 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $16.67 | 2019 | |
| Supernus Pharmaceuticals, INC. | $13.70 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Pang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.